Real-World study tests migraine Pill's consistency and satisfaction
NCT ID NCT06467370
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study follows adults with migraine who have been prescribed rimegepant (a dissolving tablet) for acute attacks. Researchers want to see how consistently the drug provides meaningful pain relief across multiple attacks and how satisfied people are with it. The study also looks at whether rimegepant works well for those already taking other migraine preventives like CGRP antibodies or Botox. Participants track their symptoms and relief in a daily diary over 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- rimegepant (oral dissolving tablet)
- What this could lead to
- If successful, this study could show how reliably rimegepant eases migraine attacks in real-world use, especially for people also taking other preventives.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by factors like patient expectations or other treatments. It does not test a new drug or compare rimegepant to a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
467 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Mar 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
There are 4 subpopulations in this study: 1. participants using rimegepant and no prophylactic 2. participants using rimegepant with background prophylaxis of OMPM 3. participants using rimegepant with background prophylaxis of mAbs 4. participants using rimegepant with background prophylaxis of Botox.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female or male patients with migraine ≥18 years old * Having received a prescription for rimegepant for acute treatment * Experienced between 3 and 14 Headache days in the last 30 days * Planning to use rimegepant for attacks happening during the next 30 days Exclusion Criteria: * Report currently using rimegepant as preventive * Report currently using concomitantly onabotulinumtoxin and any of the mAbs * Currently participating in a Migraine-related clinical trial * Reports a diagnosis from a doctor or other health professional of cluster headache, post-traumatic headache, new daily persistent headache, or hemicrania continua
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your toothpaste be triggering migraines? trial puts it to the test
- Can sleep, neck pain, and fatigue explain Migraine's daily toll?
- Do Gender-Affirming hormones trigger headaches? thai survey probes the question
- Can a pill stop a migraine in two hours?
- Can tai chi or acupuncture rewire the migraine brain?
- Could a migraine injection also heal caregiver burnout?